Literature DB >> 14691044

Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents.

Benoit Drolet1, Chantale Simard, Dan M Roden.   

Abstract

BACKGROUND: Cases of QT prolongation, torsades de pointes, and sudden death have been reported with arsenic trioxide (As2O3), a highly effective agent for acute promyelocytic leukemia. In this study, we evaluated the effects of As2O3 on repolarizing cardiac ion currents. METHODS AND
RESULTS: In HERG- or KCNQ1+KCNE1-transfected CHO cells (n=32; total), As2O3 caused concentration-dependent block of both IKr and IKs, with an IC50 for tail current block of 0.14+/-0.01 micromol/L for IKr and 1.13+/-0.06 micromol/L for IKs. In contrast to other QT-prolonging drugs, As2O3 also activated a time-independent current that additional experiments identified as IK-ATP.
CONCLUSIONS: As2O3 blocks both IKr and IKs at clinically relevant concentrations. On the other hand, it also activates IK-ATP, which maintains normal repolarization. We infer that variability in the extent of QT interval prolongation and onset of ventricular arrhythmias during arsenic therapy represents competing effects to block and activate multiple repolarizing potassium currents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14691044     DOI: 10.1161/01.CIR.0000109484.00668.CE

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  25 in total

Review 1.  Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death.

Authors:  Deborah L Wolbrette
Journal:  Curr Cardiol Rep       Date:  2004-09       Impact factor: 2.931

2.  Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy.

Authors:  Kensuke Naito; Miki Kobayashi; Naohi Sahara; Kazuyuki Shigeno; Satoki Nakamura; Kaori Shinjo; Tadasu Tobita; Akihiro Takeshita; Ryuzo Ohno; Kazunori Ohnishi
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

3.  Neovascularization and angiogenic gene expression following chronic arsenic exposure in mice.

Authors:  Nicole V Soucy; Debra Mayka; Linda R Klei; Antonia A Nemec; John A Bauer; Aaron Barchowsky
Journal:  Cardiovasc Toxicol       Date:  2005       Impact factor: 3.231

4.  Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome.

Authors:  Lee L Eckhardt; Sridharan Rajamani; Craig T January
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

5.  Association of low-moderate urine arsenic and QT interval: Cross-sectional and longitudinal evidence from the Strong Heart Study.

Authors:  Katherine A Moon; Yiyi Zhang; Eliseo Guallar; Kevin A Francesconi; Walter Goessler; Jason G Umans; Lyle G Best; Barbara V Howard; Richard B Devereux; Peter M Okin; Ana Navas-Acien
Journal:  Environ Pollut       Date:  2018-05-26       Impact factor: 8.071

Review 6.  [Proarrhythmic adverse effects of nonarrhythmic drugs].

Authors:  C G Jungbauer; L S Maier
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2019-08-23

Review 7.  QT Interval Prolongation Associated With Cytotoxic and Targeted Cancer Therapeutics.

Authors:  Sanjay Chandrasekhar; Michael G Fradley
Journal:  Curr Treat Options Oncol       Date:  2019-05-25

8.  Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.

Authors:  S Rajamani; L L Eckhardt; C R Valdivia; C A Klemens; B M Gillman; C L Anderson; K M Holzem; B P Delisle; B D Anson; J C Makielski; C T January
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

Review 9.  Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias.

Authors:  J R Giudicessi; M J Ackerman; M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2018-02-14       Impact factor: 3.598

10.  Antiarrhythmic drug-induced internalization of the atrial-specific k+ channel kv1.5.

Authors:  Sarah M Schumacher; Dyke P McEwen; Lian Zhang; Kristin L Arendt; Kristin M Van Genderen; Jeffrey R Martens
Journal:  Circ Res       Date:  2009-05-14       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.